In December 2019, an outbreak emerged of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) which leads to coronavirus disease 2019 (COVID-19). The World Health …

Introduction The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has
been widely used in a two-dose schedule. We assessed whether a third dose of the …

The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has captivated the globe's attention since its emergence in 2019. This highly …

Background The use of an inactivated severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide …

Background More effective vaccine candidates against variants of concern as a booster
dose are needed in people primed with two-dose inactivated COVID-19 vaccines. Methods …

Despite the availability of the ChAdOx1-S booster vaccine, little is known about the real-
world effectiveness although clinical trials have demonstrated enhanced immunity following …

Studies among people with multiple sclerosis (pwMS) receiving disease-modifying therapies
(DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination policies …

The objective of this study is to explore the real-world effectiveness of various vaccine
regimens to tackle the epidemic of severe acute respiratory syndrome coronavirus 2 (SARS …

A prime–boost strategy of COVID-19 vaccines brings hope to limit the spread of SARS-CoV-
2, while the immunogenicity of the vaccines is waning over time. Whether a booster dose of …

Background It is essential to know about immune response levels after booster doses of the
two different types of vaccines, mRNA, and the inactivated, currently used against COVID …